XML 52 R34.htm IDEA: XBRL DOCUMENT v3.25.1
INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS – RELATED PARTY TRANSACTIONS (Tables)
12 Months Ended
Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
SCHEDULE OF CONDENSED INCOME STATEMENT

The unaudited condensed results of operations information of Melt is summarized below:

 

   2024   2023 
   For the Years Ended December 31, 
   2024   2023 
Revenues, net  $-   $- 
Loss from operations  $(13,687,000)  $(7,581,000)
Net loss  $(13,238,000)  $(11,271,000)
SCHEDULE OF CONDENSED BALANCE SHEET

The unaudited condensed balance sheet information of Melt is summarized below:

 

   2024   2023 
   December 31, 
   2024   2023 
Current assets  $3,068,000   $13,404,000 
Total assets  $3,068,000   $13,404,000 
           
Total liabilities  $3,008,000   $3,922,000 
Total preferred stock and stockholders’ equity   60,000    9,482,000 
Total liabilities and stockholders’ equity  $3,068,000   $13,404,000